Prestige Consumer Healthcare reported fiscal second-quarter 2027 revenue growth, supported by its recent Breathe Right and LaCorium acquisitions, while sales declined modestly after excluding those deals and currency effects. Adjusted earnings per share rose from a year earlier, even as reported profit fell.
The company also updated its full-year outlook, forecasting fiscal 2027 revenue of $1.28 billion to $1.29 billion and adjusted diluted earnings per share of $4.48 to $4.55.
Key details
- Revenue rose 22.7% to $336.3 million in the quarter ended Sept. 30, from $274.1 million a year earlier. The Breathe Right and LaCorium acquisitions contributed $65.1 million.
- Excluding acquisitions and foreign-currency effects, revenue fell 1.6%. Prestige attributed the comparison in part to expected order-timing effects from the first quarter and a decline in Clear Eyes.
- Adjusted diluted earnings per share increased to $1.13 from $1.07, a gain of about 5.6%.
- Reported net income declined to $25.3 million, or $0.53 per diluted share, from $42.2 million, or $0.86 per share, a year earlier.
- Prestige said the Breathe Right and LaCorium businesses performed as expected in their first full quarter under its ownership. The acquisitions closed in June and July, respectively.
- CEO Ron Lombardi cited strength in the company’s established brands and early contributions from the acquisitions, along with consumption growth across sales channels, including e-commerce.
- The company’s fiscal 2027 outlook is $1.28 billion to $1.29 billion in revenue and $4.48 to $4.55 in adjusted diluted EPS.
Plain-English implications
The acquisitions account for much of the headline revenue increase: without their contribution and currency effects, sales were slightly lower year over year. Adjusted EPS growth indicates improvement on the company’s adjusted measure, while reported profit and diluted EPS were lower than a year earlier.